S. 3081 · Where this bill is now
In committee
Introduced in the Senate, Oct 30, 2025
What this bill does
In plain words · AI-written from the official summarySpeeds approval for drugs already okay elsewhere
This bill creates a faster path for drugs, biological products, and medical devices to be sold in the U.S. if they're already approved in certain other countries. To use this streamlined approval, a company would need to show that the product has been approved in one of those specified countries, hasn't been pulled from any of those markets due to safety or effectiveness problems, and that there's an unmet medical need for it in the U.S. The FDA would have 30 days to decide whether to approve it under this process, though Congress could override an FDA decline with a special vote.
How it affects you
If you have a serious health condition that currently has no good treatment options available in the U.S., this could potentially make a foreign-approved treatment available to you faster than the standard FDA approval process. Patients and doctors would have access to more medication choices, though the FDA still maintains the ability to reject products it considers unsafe or ineffective, and could require additional studies even after approval.
Read the official summary (Introduced in Senate, Oct 30, 2025)
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
This bill establishes a reciprocal marketing approval process that allows for the sale of a drug, biological product, or medical device that has not been approved by the Food and Drug Administration (FDA) if the product is approved for sale in another country and there is an unmet need for the product.
Specifically, in order to receive reciprocal approval, the bill requires the product's sponsor to demonstrate, among other things, that (1) the product has been approved in one of the countries specified in the bill, (2) neither the FDA nor any of the specified countries have withdrawn approval for the product because of safety or effectiveness concerns, and (3) there is a public health or unmet medical need for the product.
The FDA may decline approval if it determines that the product is not safe or effective. The FDA may condition reciprocal approval on the conduct of postmarket studies.
The FDA must issue a decision on whether to grant a request for reciprocal marketing approval within 30 days of receiving the request.
Congress may pass a joint resolution to grant reciprocal marketing approval of a product that the FDA declines to approve through the reciprocal process.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
1st SessionS. 3081
A BILL
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
Sponsor: Sen. Ted Cruz (R-TX) · Introduced Oct 30, 2025 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Oct 30, 2025: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions.”